about
Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods.HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype.Oral health after breast cancer treatment in postmenopausal women.Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients.Trastuzumab-induced myocardiotoxicity mimicking acute coronary syndromeMetastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases.Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors.Future Perspectives for Uterine Cervical Cancer Treatment based on Integrative Genomic and Molecular Characterizations.ABCG2 is a potential marker of tumor-initiating cells in breast cancer.Epithelial mesenchymal transition during the neoplastic transformation of human breast epithelial cells by estrogen.IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment.[Age as an independent prognostic factor in breast cancer].Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.[Breast cancer screening in Brazil: there is still time to rethink].Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer.Genetic profile analysis of tumor stem cells in locally advanced breast cancer.Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up.CD44+/CD24- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast.Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumorPrimary adenocarcinoma of the fallopian tube as an incidental finding during surgery in a postmenopausal patient with unspecific pelvic painDevelopment of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous TrastuzumabBreast Conserving Treatment in Early Breast Cancer: Impact of Local Recurrence Pattern on Patient SurvivalThe Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.Breast conserving surgery after neoadjuvant therapy for large primary breast cancerSafety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients[Abdominopelvic desmoid tumor][Breast cancer surgery: an old-fashioned procedure for a rising public health problem][Epidemiology of breast cancer][Breast cancer: a future challenge for health systems in developing countries]Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancerVolume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy[The search for the breast cancer cure: shall we start all over again?]Current Breast Cancer Screening Scenario in BrazilCAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapyMammography Coverage and Tumor Stage in the Opportunistic Screening ContextTranscriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu
P50
Q30439630-CB0BF846-139A-464A-A9F1-5CFC80C63F5CQ33275622-BC08591C-D081-4CA6-9BC6-B8176A92F4CEQ33767021-F9E18D00-5D40-442B-A347-98FD3A3AAEF0Q34457768-5B2B1C53-3C84-461A-9125-62EF9D5FD141Q34700395-07FC8219-B235-4E7A-99B3-DED6BA4F5F83Q35179664-B9A28851-CED5-4229-952B-AFC8487A242BQ35998239-D0F7A2A3-086A-49F9-B5A7-470098061F13Q36706560-B4FC66D8-92A8-4E90-AF59-801734C6F65FQ37119643-0745740D-4444-4F57-90CD-19D3078C5B77Q37638082-A473EF08-3D6F-4B22-8919-B9E56D36EAC5Q38738434-0643FF38-4F83-4042-A322-61B6A8D0E86FQ38862117-C4E6E79C-89F7-4C1D-AC3D-8FF08A7DEA2DQ40085067-635D8C30-E7BE-4A45-A88F-FC037FD6D0B1Q41549864-0486A054-C140-460B-B270-955AE4B604F4Q43619064-8F7E6ABF-2209-4DB9-9A38-C39B6AA98112Q43924266-5A9E68F3-4895-4193-BA16-85CC44D9E2ECQ44458342-BD1DA7AC-C38F-46D1-A2C4-D97437905F82Q45982762-2CD4FC3F-947D-4717-A1B4-2C7E4F0EA068Q46754727-D11D5BC7-7F55-476B-AF24-075DC6B041D7Q50537157-24C64E99-83BA-4ABF-B2BE-91FA6F653C6FQ53237163-B66CD6A0-BE05-4EFA-BA22-F706B9CB64B8Q56897477-6369DE7E-6831-4329-9448-C107F619A15FQ57646440-3AB02584-D573-4CA7-A3DF-8925F6EAE202Q58583000-26E5A2E9-B9B2-4FF9-A91D-A5DEDE89DA2FQ61965575-BB28C3A2-C006-42F4-BCAD-8E499CB07202Q64882616-41F6EC84-1F3E-49A6-9CD2-6FD495B11632Q80785219-C53D4AA7-BD7F-49D7-9F42-33CEA3A4E39CQ83291507-42B27E96-DA80-4FC1-BE3B-C6E302DE604FQ83611981-89EB053A-7B1C-432F-8EF4-E4384ACEE16FQ83833784-BBDEBEB0-84D5-4FB8-B656-E170C068C99BQ84382227-6533851F-2B0A-4836-AAAE-B58AD4B79423Q85191522-E0F66C4C-8E1A-4A93-9404-66277FAA8BDBQ85209476-42BDF4BB-507D-4D73-92BF-6C128949796BQ87074940-FC81D709-B2C6-492A-AD25-3E0E0AF2631EQ87515230-14AC67C1-B64F-4271-B5DE-3C4ED210E1D8Q91348790-BE9A3B6E-5FBC-40C4-AA27-E8EF07FF6AFFQ91650469-23218FD0-8BCF-47B3-9DE7-DA7623644400Q92323639-D6404959-FE22-4F25-941A-2499F3455268Q92669055-B6604537-A79A-4065-8E52-0D2C7B5D31F6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Guimarães Tiezzi
@ast
Daniel Guimarães Tiezzi
@en
Daniel Guimarães Tiezzi
@es
Daniel Guimarães Tiezzi
@nl
Daniel Guimarães Tiezzi
@sl
type
label
Daniel Guimarães Tiezzi
@ast
Daniel Guimarães Tiezzi
@en
Daniel Guimarães Tiezzi
@es
Daniel Guimarães Tiezzi
@nl
Daniel Guimarães Tiezzi
@sl
prefLabel
Daniel Guimarães Tiezzi
@ast
Daniel Guimarães Tiezzi
@en
Daniel Guimarães Tiezzi
@es
Daniel Guimarães Tiezzi
@nl
Daniel Guimarães Tiezzi
@sl
P106
P21
P31
P496
0000-0002-2660-0093